India Pharma Outlook Team | Monday, 12 June 2023
A current Active Pharmaceutical Ingredient (API) production plant in Denmark will be expanded as part of Novo Nordisk's announced plans to invest 15.9 billion Danish kroner beginning in 2023 for the company's future portfolio of major chronic diseases. The investment takes place as Novo Nordisk celebrates the 100th anniversary of its establishment in Denmark, where more than 21,000 employees, or almost half of the company's global workforce2, are still employed.
Most of these workers are employed by various production facilities. The investment in Hillerd, Denmark will boost Novo Nordisk's production capacity, improve its ability to fulfil future market demands, and play a significant role in the company's future clinical late-phase product portfolio development. “This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide,” said Henrik Wulff, executive vice president of Product Supply, Quality & IT.
“The investment announced today confirms Hillerød and Denmark as cornerstones in our global footprint, and I would like to take this opportunity to thank the Danish Government and Parliament for their continued focus on ensuring good and stable infrastructure and supplies – allowing us to continue to expand our production capacity to the benefit of patients living with serious chronic diseases. The new building, which will be about 65,000 m2, will be built as a multi-product facility with the most flexibility possible to accommodate new processes and display cutting-edge technology and working conditions.
The building will concentrate on providing the highest quality to patients worldwide in an effective and environmentally friendly manner as a future-proof and cost-effective hospital. This will be accomplished by creating compact and ideal process flows, which will significantly reduce the amount of water and energy used3.
, CDSCO.jpg)
.jpg)